Kumar Neil 4
4 · BridgeBio Pharma, Inc. · Filed Mar 16, 2026
Research Summary
AI-generated summary of this filing
BridgeBio (BBIO) CEO Neil Kumar Sells 80,000 Shares
What Happened Neil Kumar, CEO of BridgeBio Pharma (BBIO), sold a total of 80,000 shares in multiple transactions on March 12–13, 2026, generating roughly $5.50 million in proceeds. The trades were reported as open-market (sale) transactions, with individual trades at prices between approximately $67.76 and $70.18 per share (detailed per-trade prices in the filing). The sales were effected pursuant to a Rule 10b5‑1 trading plan adopted March 31, 2025, indicating pre-scheduled dispositions rather than discretionary, same-day sales.
Key Details
- Dates: March 12–13, 2026 (Form filed March 16, 2026).
- Total shares sold: 80,000; approximate proceeds: $5,501,068.
- Price range reported (per filing footnotes): about $67.76 to $70.18 per share; the filing provides weighted-average ranges and offers to provide per-price breakdowns on request.
- Transaction type: S = Sale (open market/private sale as reported); effected under a Rule 10b5‑1 plan (footnote F1).
- Beneficial ownership note: filing includes a disclaimer (F3) that the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
- Timeliness: Filed March 16, 2026 for trades on Mar 12–13 — reported within the normal Section 16 timing window.
Context Sales under an established 10b5‑1 plan are typically pre-planned and are treated as routine dispositions; they do not necessarily indicate the insider’s current views on the company’s prospects. Retail investors should view this as an insider sale (liquidity) rather than a purchase signal. If you need the exact per-trade price breakdown, the filing indicates the reporting person will provide that information upon request.
Insider Transaction Report
Form 4
Kumar Neil
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-03-12$68.48/sh−14,337$981,809→ 661,349 total(indirect: By Trust) - Sale
Common Stock
[F1][F4][F3]2026-03-12$69.32/sh−5,363$371,750→ 655,986 total(indirect: By Trust) - Sale
Common Stock
[F1][F5][F3]2026-03-12$70.15/sh−300$21,045→ 655,686 total(indirect: By Trust) - Sale
Common Stock
[F1][F6][F3]2026-03-12$68.47/sh−13,885$950,687→ 4,464,562 total(indirect: By Trust) - Sale
Common Stock
[F1][F7][F3]2026-03-12$69.29/sh−5,815$402,929→ 4,458,747 total(indirect: By Trust) - Sale
Common Stock
[F1][F5][F3]2026-03-12$70.15/sh−300$21,045→ 4,458,447 total(indirect: By Trust) - Sale
Common Stock
[F1][F8][F3]2026-03-13$68.36/sh−9,690$662,441→ 645,996 total(indirect: By Trust) - Sale
Common Stock
[F1][F9][F3]2026-03-13$69.20/sh−10,310$713,449→ 635,686 total(indirect: By Trust) - Sale
Common Stock
[F1][F10][F3]2026-03-13$68.39/sh−10,241$700,345→ 4,448,206 total(indirect: By Trust) - Sale
Common Stock
[F1][F11][F3]2026-03-13$69.23/sh−9,759$675,568→ 4,438,447 total(indirect: By Trust)
Holdings
- 234,451
Common Stock
Footnotes (11)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
- [F10]Represents the weighted average sale price of the shares sold from $67.82 to $68.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F11]Represents the weighted average sale price of the shares sold from $68.82 to $69.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F2]Represents the weighted average sale price of the shares sold from $67.935 to $68.93 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- [F4]Represents the weighted average sale price of the shares sold from $68.94 to $69.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F5]Represents the weighted average sale price of the shares sold from $70.1 to $70.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F6]Represents the weighted average sale price of the shares sold from $67.935 to $68.92 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F7]Represents the weighted average sale price of the shares sold from $68.94 to $69.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F8]Represents the weighted average sale price of the shares sold from $67.76 to $68.74 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F9]Represents the weighted average sale price of the shares sold from $68.76 to $69.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Signature
/s/ Will Solis, Attorney-in-Fact|2026-03-16